Abstract:

Purpose: Our study aims to compare clinical and laboratory findings in multiple myeloma patients with the level of serum B12 in the diagnosis. Patients were divided into two groups, low and normal according to the levels of vitamin B12.  The data was compared with independent sampling T, Mann Whitney U and ki-core tests according to the distribution characteristics. Results: A retrospective file review found vitamin B12 deficiency in 41 (32%) of 128 patients involved in the study. The bone marrow plasma rate was significantly lower in this group; the median was 30% and 50% (p: 0.024). There was no difference between the two groups in terms of age, total protein, lactate dehydrogenase, ß2-microglobulin, calcium, creatine, albumin and lithium damage. However, the group with low levels of vitamin B12 was diagnosed with anemia in 11 patients (26.8 percent) and 44 patients (50.5 percent) in the normal group. The high rate of anemia in the normal group was statically significant (p: 0,019). There is no difference between the ISS and the R-ISS stages in terms of vitamin B12. The result: Low vitamin B12 levels have a lower rate of bone marrow plasma cells. Our data has not shown a clinical reflection of this. Treatment response, survival and recurrence rates are required for clinical data assessment studies.